UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000007996
Receipt number R000009411
Scientific Title A study on the preventive effect of radiation pneumonitis and the effect on serum biomarker levels with long-term, low-dose macrolide (Clarithromycin) therapy (multicenter randomized comparison).
Date of disclosure of the study information 2012/05/23
Last modified on 2019/03/04 18:02:26

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A study on the preventive effect of radiation pneumonitis and the effect on serum biomarker levels with long-term, low-dose macrolide (Clarithromycin) therapy (multicenter randomized comparison).

Acronym

A study on the preventive effect of radiation pneumonitis with long-term, low-dose macrolide therapy (YCRG0005).

Scientific Title

A study on the preventive effect of radiation pneumonitis and the effect on serum biomarker levels with long-term, low-dose macrolide (Clarithromycin) therapy (multicenter randomized comparison).

Scientific Title:Acronym

A study on the preventive effect of radiation pneumonitis with long-term, low-dose macrolide therapy (YCRG0005).

Region

Japan


Condition

Condition

Lung cancer

Classification by specialty

Pneumology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To examine the preventive effect of long-term, low-dose macrolide therapy (Clarithromycin (CAM)) on the patients with lung cancer under chemoradiotherapy. Furthermore, to clarify the usefullness of serum biomarkers on the prediction of onset, disease severity and prognosis of radiation pneumonitis.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Phase II


Assessment

Primary outcomes

disease severity(Grade) of radiation pneumonitis with CTCAEver3.0

Key secondary outcomes

Efficacy:
1) Usefluness of various serum biomarker as indicator of disease severity of radiation pneumonitis. The biomarkers including, LDH, CRP, Type III procollagen N-terminal peptide (PIIIP), KL-6, SPD, and SPA, monocyte chemoattractant protein -1 (MCP-1), TGF-beta, IFN-gamma, HO-1, etc.
2) pulmonary function test
3) blood gas analysis
Safety:
adverse events, and their incidence.


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

No treatment

Stratification

YES

Dynamic allocation

NO

Institution consideration

Institution is considered as a block.

Blocking

YES

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

The clarithromycin group :
A clarithromycin 200mg tablet is taken once per day for 6 months from immediately after the start of irradiation therapy.

Interventions/Control_2

Without clarithromycin group: without clarithromycin medication.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >=

Gender

Male and Female

Key inclusion criteria

1. Age : >=20 or <= 75 years old
2. Performance status: 0-1
3. patient with lung cancer(stageII-III) for the purpose of chemoradiotherapy
4. patient by whom consent is got in written form about participation of the study

Key exclusion criteria

1. patient who has merged mltiple organ failure including lungs of four or more internal organs
2.patient with idiopathic pulmonary fibrosis
3. patient who has past of chemotherapy, or chest radiotherapy in the past for other cancer
4. patient with active double cancer
5. patient who take corticosteroids
6. patient with pregnant, breast- feeding, and possibility of pregnancy
7. patient who are considered inappropriate by physicians in charge
8.patient for the purpose of stereotactic radiation therapy

Target sample size

72


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Takeshi Kaneko

Organization

Yokohama City University Medical Center

Division name

Respiratory Disease Center

Zip code


Address

4-57 Urafune-cho, Minami-ku, Yokohama City, 232-0024, Japan

TEL

045-261-5656

Email

takeshi@med.yokohama-cu.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Masaharu Shinkai

Organization

Yokohama City University Medical Center

Division name

Respiratory Disease Center

Zip code


Address

4-57 Urafune-cho, Minami-ku, Yokohama City, 232-0024, Japan

TEL

045-261-5656

Homepage URL


Email

shinkai@yokohama-cu.ac.jp


Sponsor or person

Institute

Yokohama City University Medical Center

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

横浜市立大学附属市民総合医療センター(神奈川県)
防衛医科大学校病院(埼玉県)
横浜市立大学附属病院(神奈川県)
藤沢市民病院(神奈川県)
大船中央病院(神奈川県)
横浜南共済病院(神奈川県)
関東労災病院(神奈川県)
大和市立病院(神奈川県)
茅ヶ崎市立病院(神奈川県)
横浜栄共済病院(神奈川県)
国立病院横浜医療センター(神奈川県)
済生会横浜市南部病院(神奈川県)


Other administrative information

Date of disclosure of the study information

2012 Year 05 Month 23 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2011 Year 12 Month 19 Day

Date of IRB


Anticipated trial start date

2012 Year 05 Month 01 Day

Last follow-up date

2017 Year 09 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2012 Year 05 Month 21 Day

Last modified on

2019 Year 03 Month 04 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009411


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name